Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis; Study Did Not Meet Key Efficacy Objectives
Study did not meet key efficacy objectivesFavorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion, as evidenced by
Celldex tested a new medicine for itchy skin but it didn't work as well as hoped, though it was safe. When a medicine doesn't do what doctors expect, that's something to watch—it means the company needs to figure out what went wrong or try a different approach.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.